

# Michail Nikolaou MD, MSc, PhD

## Medical Oncologist

[www.michailnikolaou.com](http://www.michailnikolaou.com)

Father's name: Apostolos, Mother's name: Evageli

Address: Efranoros 4, Athens T.P.: 11635

E-mail address: mixalisnikola@gmail.com

Mobile number: 0030 6979223672

Date of Birth: 24/12/1979

Place of Birth: Karditsa

## Member of the:

ESMO, ASCO, HeSMO, HeGYO



## WORK EXPERIENCE:

07/07/2020 – Currently: Medical Oncologist in 1<sup>st</sup> Medical Oncology Department, Anti-cancer Hospital “Agios Savvas”, Athens, Greece

04/12/2019 – 06/07/20 (7 months): Medical Oncologist in University Internal Medicine Department at "ATTIKO", Athens, Greece

02/10/2017 – 03/12/2019 (2 years & 2 months): Medical Oncologist in Oncology Department at "HELENA VENIZELOU General and Maternity District Hospital", Athens, Greece

01/10/2015 – 01/10/2017 (2 years): Medical Oncologist in University Internal Medicine Department at “Hippokration” General Hospital of Athens, Greece

11/05/2015 – 13/07/2015 (2 months): Volunteer Medical Oncologist in Oncology Department at "HELENA VENIZELOU General and Maternity District Hospital", Athens, Greece

07/02/2012 - 06/02/2015 (3 years): *Medical Oncology Resident* at University Hospital of Larissa, Greece

06/07/2011 - 09/01/2012 (6 months): *Hematology Resident* at University Hospital of Athens "LAIKO", Greece

03/11/2008 - 26/04/2010 (17 months): *Internal Medicine Resident* at General Hospital of Karditsa, Greece

24/07/2007 - 14/10/2008 (15 months): *Internal Medicine Resident* at General Hospital of Trikala, Greece

16/02/2007 - 23/07/2007 (6 months): *Rural Doctor* at Health Center in Palama (Karditsa), Greece

16/11/2006 - 15/02/2007 (3 months): *Internal Medicine Resident* at General Hospital of Karditsa, Greece

08/08/2005 - 08/08/2006 (9 months): Physician in Greek Army (*Reservist Second Lieutenant*)

#### DIPLOMAS:

1. Acquisition of title of Specialty: Medical Oncologist (examination 17/04/15)

2. MHA: Administration of Health and Welfare Units - Gestionnaire d'établissements médicaux et médicosociaux

René Descartes College in collaboration with the French Public University CNAM (Conservatoire National des Arts et Métiers)

In progress (2019-2022)

3. PhD: Medicine Doctorate at the Department of Morphology, Faculty of Medicine, University of Thessaly, Greece

Thesis: "*Immunohistochemical Study of the Expression of the O-linked N-acetylglucosamine containing Epitope-H in the Chorionic Villi of the Placenta in missed miscarriage abortions*"  
Supervisor: Professor Dimitrios Arvanitis

4. MSc: Postgraduate Studies "Aquaculture - Aquatic Animal Organizations" Department of Veterinary University of Thessaly in Partnership with the Department of Aquaculture and Fisheries, TEI Epirus, Greece

Thesis: "*Cancer of Aquatic Organisms*"

5. MD: *Medical Degree* of Aristotle University of Thessaloniki, Greece (21/04/2005)

OTHER WORK EXPERIENCE - QUALIFICATIONS:

**-President of the non-profit company IEEE**

<https://www.i-eee.gr/>

**- Elected Special Secretary of the HeSMO (Hellenic Society of Medical Oncology) (2021-2023)**

**- Elected President of the HeGYO (Greek Young Oncologists Group - ONEO) (2016 - 2019)**

**- Elected Treasurer of the Professional Association of Greek Medical Oncologists (ΕΠΠΟΕ) (2017 - 2021)**

- Science Manager of the HeGYO (Greek Young Oncologists Group - ONEO) (2015 - 2016)

- Communications Manager of the HeGYO (Greek Young Oncologists Group - ONEO) (2013 - 2015)

---

- Associate Editor of Editorial Board of oncologist magazine **“Theranostics of Cancer Research”**

- Editor of Editorial Board of oncologist magazine **“International Journal of Clinical Oncology and Cancer Research”**

- Editor of Editorial Board of oncologist magazine **“Advances in Cancer Research & Clinical Imaging (ACRCI)”**

- Honourable Editor of Editorial Board of **“American Journal of Biomedical Science & Research”**

- Editor and Author of the Column HeGYO (ONEO) on the Electronic Magazine **“News of Oncology”** (2013 - 2015)

- Editor of Editorial Board of the Medical Oncology Magazine **“FCO – Forum for Clinical Oncology”** (2015 - until today)

- One of the Perpetrators, Creators and Managers of HeGYO (ONEO) Social Profile and Promotion Online

- Conference Organizer and Chairman in many congresses

---

-Financial support for a research program from HESMO 2017: Validation of Cdc6 as a Drug Target and Discovery of Small-Molecule Inhibitors with Anticancer Therapeutic Potential

-Financial support for a research program from HESMO 2017: Study of the anticancer activity of the novel derivatives triazolo- [3,4-b] -1,3,4-thiadiazoles in relation to the state of the

DNA Mismatch Repair (MMR) and the Microsatellite Instability (MSI) phenotype presenting human malignant neoplasms "

-Financial support for a research program from HESMO 2018: The role of cellular ageing in head and neck cancer. Study in patients with precancerous but also head and neck cancer before and after conservative treatment

-Financial support for a research program from HESMO 2018: The importance of dual inhibition of the RAS / PI3K / AKT and RAS / RAF / MEK / ERK molecular pathways in the treatment of pancreatic adenocarcinoma: Application of new hybrid steroidal agents with dual inhibitory activity

-Financial support for a research program from HESMO 2019: Targeting the CDC6 gene to sensitize aggressive breast cancer cells to death

-Financial support for a research program from HESMO 2019: Investigation and development of novel lactam steroid alkylators with targeted activity against Poly (ADP-ribose) polymerase (PARP) enzymes in the treatment of ovarian cancer

-----  
- Reviewer for FCO article with the title "Inframammary Approach for Skin-Sparing Mastectomy and Immediate Breast Reconstruction with a Silicone Implant". 11 March 2019 (FCO-D-18-00014)

- Reviewer for FCO article with the title "Functional and Survival Outcome of Egyptian Children and Adolescents with Malignant Bone Tumors: An Experience in a Setting of Limited Health Resource". 19 November 2018 (FCO-D-18-00001R1)

- Reviewer for FCO article with the title "Neoadjuvant Chemotherapy Followed by Concurrent Chemo- Radiotherapy in Locally Advanced Rectal Carcinoma". 10 September 2017 (FCO-D-17-00009)

- Reviewer for FCO article with the title "Living with breast cancer: Patients' journey within the Greek National Health System". 01 December 2015 (FCO-D-15-00021)

- Reviewer for FCO article with the title "Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study". 10 November 2015 (FCO-D-15-00010)

-----  
- Completed an online course (5 weeks) authorized by Duke University with the title "The Challenges of Global Health". 05 November 2015

- Completed an online course (6 weeks) authorized by University of North Carolina at Chapel Hill with the title "Epidemiology: The Basic Science of Public Health". 19 October 2015  
-----

- Participant in the ESMO Guidelines Translations for several types of Cancer in the Greek Language for Patients and their Relatives (2014 - 2015) (Head and Neck, Colorectal, Liver, Melanoma, Esophageal, Pancreatic, Prostate)

- Manager and Author in the update in Consensus for Breast Cancer in HeSMO (2015)

---

- Author of a chapter (Monograph): Vaginal Cancer for the International Oncology Book entitled: International Manual of Oncology Practice (iMOP) Principles of Medical Oncology (2nd edition). (Springer 2019) ISBN: 978-3-030-16245-0

<https://link.springer.com/book/10.1007/978-3-030-16245-0#about>

- Author of chapter: Regorafenib for the Oncology Book entitled: New Treatments in Oncology. Manual for the Management of Adverse Events. (2019) ISBN:978-618-81321-1-5

- Author of chapter: Regorafenib for the Oncology Book entitled: New Treatments in Oncology. Manual for patient information on treatments side effects. (2019) ISBN:978-618-81321-2-2

- Author of a chapter (Monograph): Genetic Mechanisms and Cancer for the book: "CANCER" Who Are You? Where do you come from? How do you live? ", Spiliotis D. Ioannis (2017) ISBN: 978-9963-274-71-0

- Author of a chapter (Monograph): Vaginal Cancer for the International Oncology Book entitled: International Manual of Oncology Practice (iMOP) Principles of Medical Oncology. (Springer 2015) ISBN: 978-3-319-21682-9

<http://www.springer.com/978-3-319-21682-9>

- Participant Author of an Informative Booklet on/for Pancreatic Cancer Patients and their Associates (2014)

- Teaching "Radiology II" Course in the Department of Medical Imaging Devices IEK Karditsa. A Booklet was produced for the Specific Taught Course Deposited in the IEK Library, Karditsa (2007)

---

- Commander at Private Surgical Hospital in Karditsa, Greece (2008 - 2017)

---

- Voluntary Teaching of the Course "Anatomy" to Volunteer Nurses at Nursing Regional Branch of Karditsa, Greek Red Cross (2010)

- Volunteer Participant: Support Program Unit Health Centers of Northern Greece in summer held by the Scientific Association of Medical Students of Greece, Thessaloniki Branch Hospital of Katerini (2003, 2001 and 2000)

PUBLICATIONS:

1) Immunotherapy of Cancer. Developments and Reference Points, an Unorthodox Approach

*M. Nikolaou, G. Nikolaou, A. Digklia, Ch. Pontas, N. Tsoukalas, G. Kyrgias, M. Tolia*

Integrative Cancer Therapies - Impact factor 3.279

2) The challenge of resistance in cancer treatment: A current overview

*M. Nikolaou, A. Pavlopoulou, A. Georgakilas, E. Kyrodimos*

Clinical and Experimental Metastasis - Impact factor 3.455

3) The O-Linked N-Acetylglucosamine Containing Epitope H (O-GlcNAcH) is Upregulated in the Trophoblastic and Downregulated in the Fibroblastic Cells in Human Chorionic Villi with Myxoid Degeneration

*M. Nikolaou, Y. Drosos, S. Havaki, D. Arvanitis, S. Sotiriou, K. Vassiou, A. Zibis, L.D. Arvanitis*

International Journal of Gynecological Pathology - Impact factor 2.006

4) The Role of E3, E4 Ubiquitin Ligase (UBE4B) in Human Pathologies

*N. Antoniou, N. Lagopati, D. I. Balourdas, M. Nikolaou, A. Papalampros, P. V.S. Vasileiou, V. Myrianthopoulos, Y. Shiloh, V. G. Gorgoulis, A. Kotsinas*

Cancers - Impact factor 6.162

5) Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients

*A. Strati, M. Nikolaou, V. Georgoulis, E. Lianidou*

Cells – Impact factor 5.656

6) Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment

*I. Messaritakis, M. Nikolaou, F. Koinis, E. Politaki, A. Koutsopoulos, E. Lagoudaki, E. K. Vetsika, V. Georgoulis, A. Kotsakis*

Lung Cancer - Impact factor 4.599

7) Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment

*I. Messaritakis, M. Nikolaou, E. Politaki, F. Koinis, E. Lagoudaki, A. Koutsopoulos, N. Georgoulia, V. Georgoulas, A. Kotsakis*

Lung Cancer - Impact factor 4.599

8) Weekly paclitaxel and carboplatin plus bevacizumab as first-line treatment of triple-negative breast cancer. A multicenter phase I-II trial by the Hellenic Oncology Research Group.

*Saloustris E., Nikolaou M., Kalbakis K., Polyzos A., Christofillakis Ch., Kentepozidis N., Pistamaltzian N., Kourousis Ch., Vamvakas L., Georgoulas V., Mavroudis D.*

Clinical Breast Cancer - Impact factor 2.816

9) Tumor Protein p53 Gene and Cardiovascular Disease

*A. Tzovaras, F. Gentimi, M. Nikolaou*

Angiology - Impact factor 3.085

10) Capecitabine, oxaliplatin, irinotecan and bevacizumab combination followed by pazopanib plus capecitabine maintenance for high-grade gastrointestinal neuroendocrine carcinomas

*E. Alifieris, J. Griniatsos, S. Delis, M. Nikolaou, C. Avgoustou, M. Panagiotidis, E. Souferi-Chronopoulou, D. Trafalis*

American Journal of Clinical Oncology - Impact factor 3.015

11) Azasteroid Alkylators as Dual Inhibitors of AKT and ERK Signaling for the Treatment of Ovarian Carcinoma

*P. Dalezis, E. Geromichalou, A. Polonifi, S. Sagredou, N. Nikoleousakos, M. Nikolaou, V. Sarli, M. Panayiotidis, D. Trafalis*

Cancers - Impact factor 6.162

12) 3,6-disubstituted 1,2,4-[3,4-b]-triazolo-1,3,4-thiadiazole derivatives with anticancer activity targeting topoisomerase II alpha

*S. Sagredou, P. Dalezis, N. Nikoleousakos, M. Nikolaou, M. Voura, S. Fountoulaki, K. Almpanakis, M. I. Panayiotidis, V. Sarli, D. T. Trafalis*

OncoTargets and Therapy - Impact factor 3.046

13) Observational study of clinical practice in patients with pancreatic adenocarcinoma in Greece

*G. Papaxoinis, A. Athanasiadis, J. Sgouros, A. Visvikis, M. Drizou, E. Kontopodis, A. Koumarianou, S. Stojanovska, G. Aravantinos, I. Korantzis, A. Ioannou, I. Varthalitis, D. Doufexis, M. Nikolaou, G. Lypas, I. Bompolaki, A. Christopoulou, M. Liontos, N. Tsoukalas, D. Mauri, N. Xenidis, P. Katsaounis, G. Oikonomopoulos, I. Boukovinas*

Journal of Oncology - Impact factor 2.206

14) Metastatic Soft Tissue Sarcoma: Current treatment landscape and future perspectives

*E. Skafida, S. Kokkali, M. Nikolaou, A. Digklia*

Expert Review of Anticancer Therapy - Impact factor 2.347

15) A case of Pseudomembranous Colitis associated with Paclitaxel and Carboplatin chemotherapy for Vulvar Cancer

*M. Nikolaou, K. Tsapakidis, V. Papadopoulos, C. Pontas, P. Michailidis, K. Tyrpanaki*

European Journal of Gynaecological Oncology - Impact factor 0.692

16) How Can We Effectively Address the Paraneoplastic Dermatomyositis: Diagnosis, Risk Factors and Treatment Options.

*I. Zerdes, M. Tolia, M. Nikolaou, N. Tsoukalas, L. Velentza, J. Hajjiannou, M. Mitsis, G. Kyrgias.*

JBUON - Impact factor 1.766

17) Addressing the post-irradiation hypothalamic-pituitary endocrine abnormalities of brain tumors in pediatric patients

*L. Velentza, M. Tolia, C. Christakou, M. Nikolaou, I. Zerdes, N. Tsoukalas, J. Hajjiannou, K. Tsanadis, G. Rigas, M. Mitsis, K. Theodorou, K. Pistevou-Gombaki, P. Tsekeris, G. Kyrgias*

JBUON - Impact factor 1.766



18) Stage-II Thymoma and emergency coronary artery bypass. To irradiate or not to irradiate to avoid radiation induced vascular injury? Case Report and Literature Review

*I. Kouerinis, M. Tolia, F. Zagouri, M. Nikolaou, N. Tsoukalas, G. Kyrgias, M. Dimopoulos, C. Vlachopoulos, I. Karathanassis, M. Zoubouli, I. Kokakis, V. Kouloulias, K. Triantafyllou*

JBUON - Impact factor 1.766

19) Health related quality of life of young women with breast cancer. Review of literature

*A. Yfantis, G. Intas, M. Tolia, M. Nikolaou, N. Tsoukalas, M. Lympéri, G. Kyrgias, G. Zografos, M. Kontos*

JBUON - Impact factor 1.766

20) Percutaneous-computed-tomography- guided localization of pulmonary nodules with hook wire prior to video-assisted thoracoscopic surgery

*S. Manouvelou, E. Mosa, M. Tolia, N. Tsoukalas, M. Nikolaou, G. Nikolaou, A. Dountsis, E. Andriotis, K. Vasilikos, G. Kyrgias*

JBUON - Impact factor 1.766

21) Utilizing Yoga in oncologic patients treated with Radiotherapy: Review.

*M. Tolia, N. Tsoukalas, M. Nikolaou, E. Mosa, I. Nazos, A. Poultsidi, J. Hajiioannou, K. Tsanadis, D. Spyropoulou, N. Charalampakis, D. Kardamakís, V. Kouloulias, K. Pistevou-Gombaki, G. Kyrgias*

Indian Journal of Palliative Care - Impact factor 0.82

22) Vaginal Stenosis after Radiation Therapy for Pelvic Cancer: Prevention and Treatment Options - A Review of the Current Literature

*D. Charatsi, M. Tolia, P. Vanakara, N. Tsoukalas, M. Nikolaou, D. Korfias, G. Nikolaou, A. Daponte, G. Kyrgias*

European Journal of Gynaecological Oncology - Impact factor 0.692

23) Clinical value of significance of Hypoxia Inducible Factor-1 $\alpha$ , Glucose Transporter-1 and Carbonic Anhydrase IX in rectal cancer after preoperative chemoradiotherapy.

*D. – I. Vitoratou, M.Tolia, P. Liakos, N. Tsoukalas, C. Giaginis, M. Nikolaou, G. Nikolaou, G. Rigas, K. Psarianos, A. Lioupis, G. Kyrgias*

JBUON - Impact factor 1.766

24) Breast radiotherapy and early adverse cardiac effects. The role of serum biomarkers and strain echocardiography

*A. Gkantaifi, C. Papadopoulos, D. Spyropoulou, M. Toumpourleka, G. Iliadis, D. Kardamakis, M. Nikolaou, N. Tsoukalas, G. Kyrgias, M. Tolia*

Anticancer Research - Impact factor 1.865

25) Evaluation of Quality of Life Outcomes Following Palliative Radiotherapy in Bone Metastases: A Literature Review

*C. Koufopoulou, E. Mosa, N. Charalampakis, M. Nikolaou, N. Tsoukalas, I. Nixon, H. H. Saraireh, J. Hajjiannou, D. Kardamakis, G. Kyrgias, M. Tolia*

JBUON - Impact factor 1.766

26) Effects of a novel thiadiazole derivative with high anticancer activity on cancer cell immunogenic markers mismatch repair system, PD-L1 expression, tumor mutation burden

*S. Sagredou, P. Dalezis, E. Papadopolou, M. Voura, M. Deligiorgi, M. Nikolaou, M. Panayiotidis, G. Nasioulas, V. Sarli, D. Trafalis*

Pharmaceutics - Impact factor 4.421

27) Hepatocellular Carcinoma: The Changing Landscape of Treatment Options

*A. Koulouris, E. Pappa, V. Spyrou, A. Troullinou, M. Nikolaou*

Journal of Hepatocellular Carcinoma - Impact factor 5.828

28) RNA-based CTC analysis provides prognostic information in metastatic breast cancer

*A. Strati, M. Nikolaou, V. Gorgoulis, E. Lianidou*

Diagnostics - Impact factor 3.110

29) The Real Impact of Novel Immunotherapy in Cancer. An overview of the 10 last years' experience

*A. Koulouris, C. Tsagkaris, M. Nikolaou*

Toxins - Impact factor 4.546

30) Prognostic significance of a combined gene expression analysis in EpCAM(+) CTCs in metastatic breast cancer based on a ten year follow-up

*A. Strati, M. Nikolaou, V. Gorgoulis, E. Lianidou*

Research Square

31) Objective response to first line treatment as a predictor for overall survival in metastatic breast cancer: a retrospective analysis from two centers over a 25-year period

*A. Matikas, A. Kotsakis, M. Perraki, D. Hatzidaki, K. Kalbakis, E. Kontopodis, M. Nikolaou, V. Georgoulis*

Breast Care - Impact factor 2.860

32) Vaccine third dose and cancer patients: necessity or luxury?

*G. Pappas, E. Saloustros, A. Boutis, N. Tsoukalas, M. Nikolaou, A. Christopoulou, S. Agelaki, I. Boukovinas, A. Ardavanis, Z. Saridaki*

ESMO Open - Impact factor 6.540

33) Vaginal Dilator Use to Promote Sexual Wellbeing After Radiotherapy in Gynaecological Cancer Survivors: A Prospective Observational Study

*D. Charatsi, P. Vanakara, M. Nikolaou, A. Evaggelopoulou, D. Korfias, F. Simopoulou, N. Charalampakis, D. Schizas, A. Daponte, G. Kyrgias, M. Tolia*

International Journal of Cancer Science & Therapy - Impact factor 1.17

34) Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature

*K. Kamposioras, P. Ntellas, M. Nikolaou, T. Germetaki, I. Gazouli, K. Dadouli, G. Zarkavelis, A. L. Amylidi, M. Tolia, D. Mauri*

Journal of the National Cancer Institute - Impact factor 13.506

35) Inmate cancer patients: Highlighting the importance of a holistic approach to oncological care

*M. Tolia, E. Symvoulakis, K. Kamposioras, D. Mauri, A. Skoutari, P. Volkos, D. Schizas, A. Spanos, I. Kokakis, N. Tsoukalas, N. Charalampakis, F. Cuccia, F. Alongi, R. de Mello, K. Antoniou, T. Hyphantis, I. Nixon, D. Matthaios, M. Nikolaou, F. de Lorenzo, K. Apostolidis*

JBUON - Impact factor 2.533

36) Detection of circulating tumor cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer

*A. Matikas, A. Kotsakis, S. Apostolaki, H. Politaki, M. Perraki, K. Kalbakis, M. Nikolaou, P. Economopoulou, D. Hatzidaki, V. Georgoulas*

British journal of cancer (BJC) - Impact factor 7.64

**Abstract which Published in Annals of Oncology (with Impact factor 32.976):**

1) The role of Bevacizumab plus Front-line Chemotherapy in patients with malignant

Ascites of Ovarian cancer.

*M. Nikolaou, N. Ziras, I. Athanasiadis, A. Ardavanis, M. Vaslamatzis, N. Kentepozidis, P. Makrantonakis, A.N. Christopoulou, V. Michalaki, A. Polizos, C. Emmanouilidis, V. Georgoulas*

2) Final results of weekly paclitaxel and carboplatin plus bevacizumab as first-line treatment of triple-negative breast cancer. A multicenter phase I-II trial by the Hellenic Oncology Research Group

*M. Nikolaou, E. Saloustros, A. Polyzos, C. Christophyllakis, N. Kentepozidis, L. Vamvakas, K. Kalbakis, S. Agelaki, V. Georgoulas, D. Mavroudis*

3) Education in oncology and career development in the web-era technology: a European survey conducted by the Hellenic Group of Young Oncologists (HeGYO)

*N.G. Tsoukalas, K. Kamposioras, G. Papaxoinis, E. Aravantinou-Fatorou, A. Korogiannos, V. Papadopoulos, G. Lazaridis, M. Nikolaou, E. Voulgaris, E. Bournakis, K. Tsigaridas, M. Lontos, E. Papageorgiou, N. Chatzifoti, P. Zaxaropoulou, A. Athanasiadis, I. Varthalitis*

4) Highlighting differences in education satisfaction and professional development between medical and clinical oncologists in Europe. A European survey conducted by the Hellenic Group of Young Oncologists (HeGYO)

*E. Aravantinou Fatorou, G. Papaxoinis, K. Kamposioras, A. Korogiannos, V. Papadopoulos, G. Lazaridis, M. Nikolaou, E. Voulgaris, E. Bournakis, K. Tsigaridas, M. Lontos, E. Pantavou, N. Chatzifoti, P. Zaxaropoulou, I. Varthalitis, A. Athanasiadis, N.G. Tsoukalas*

5) New treatments in Oncology: Clinical practice regarding the management of Adverse Events (AEs). Results from a survey conducted by the Hellenic Group of Young Oncologists (HeGYO)

*M. Lontos, F. Koinis, G. Chatsidis, K. Kamposioras, G. Papaxoinis, M. Nikolaou, K. Tsigaridas, E. Voulgaris, E. Pantavou, G. Aravantinos, A. Ardavanis, I. Boukovinas, E. Galani, S. Angelaki, G. Mountzios, Z. Saridaki, I. Varthalitis, N. Tsoukalas*

#### STUDIES (Clinical Trials)

- 1) Prevent study. The prevalence of asymptomatic deep vein thrombosis (DVT) in cancer patients. Data coming from day-to-day clinical practice in Greece (University Hospital of Larissa)
- 2) TESARO - BRAVO. A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. (Sub-Investigator)  
<https://clinicaltrials.gov/ct2/show/NCT01905592?term=TESARO+-+BRAVO&rank=1>
- 3) PUMA. A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer. (Sub-Investigator)  
<https://clinicaltrials.gov/ct2/show/NCT00878709?term=Neratinib+%28HKI-272%29+After+Trastuzumab&rank=1>
- 4) ELUXA 3. An international, randomised, multi-centre, active-controlled, open-label Phase III study evaluating the efficacy of BI 1482694 versus afatinib as first line treatment in patients with locally advanced or metastatic non-small cell lung cancer carrying epidermal growth factor receptor activating mutations. (Sub-Investigator)  
<http://adisinsight.springer.com/trials/700273106>
- 5) ELI LILLY (I4T-MC-JVCP RAM EAP). An International Single-Arm Protocol to Provide Expanded Access to Ramucirumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression after prior Fluoropyrimidine and/or Platinum-Containing Chemotherapy. (Sub-Investigator)  
<https://clinicaltrials.gov/ct2/show/NCT02065765?term=I4T-MC-JVCP&rank=1>
- 6) FUJIFILM study. A Randomized, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® in 1st Line Treatment for Patients with

Advanced/Recurrent Non Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin. (Sub-Investigator)

<https://clinicaltrials.gov/ct2/show/NCT02810457?term=FKB238&rank=1>

AVANA Investigator Meeting. Took place 30 June – 1 July 2016, in Athens, Greece (Sub-Investigator)

- 7) GO29432 study. A phase III, open-label, randomized study of MPDL3280A (ANTI-PDL1 antibody) compared with Gemcitabine + Cisplatin or Carboplatin for PD-L1-Selected, chemotherapy naïve patients with stage IV Squamous Non-Small Cell Lung Cancer. (Sub-Investigator)

<https://clinicaltrials.gov/ct2/show/NCT02409355?term=GO29432+study&rank=1>

- 8) 1301 study. Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD). (Sub-Investigator)

<https://clinicaltrials.gov/ct2/show/NCT02485691?term=cabazitaxel&cntry=GR&rank=5>

- 9) AZD9291. Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC. (Sub-Investigator)

<https://clinicaltrials.gov/ct2/show/NCT02771314?term=AZD+osimertinib&cntry=GR&rank=1>

- 10) MINOAS study. A trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment (MINOAS). (Sub-Investigator)

<https://clinicaltrials.gov/ct2/show/NCT02624726>

- 11) Non-invasive study of clinical practice in Greece in the Treatment of Metastatic Pancreatic Cancer – HeSMO. (Sub-Investigator)

#### CONTINUING MEDICAL EDUCATION

Participation in many Oncology Conferences from 2012

More than 180 Oral Presentation in Congresses

More than 50 Poster Presentation in National & International Congress


More than 2500 CME - CPD points from the Panhellenic Medical Association since 2012

More than 500 Cat1 ESMO - MORA points since 2012

Certificates of Participation in the European School of Oncology "ESO e-learning"

Good Clinical Practis Certification - 10 Septemper 2020

Invastigator Site Personnel ICH GCP Training Certificate

A handwritten signature in black ink, appearing to read 'Michail Nikolaou', with a long horizontal stroke extending to the right.

**Michail Nikolaou**

*MD, MSc, PhD*

04-01-2022